Read by QxMD icon Read

Premenopausal Breast Cancer

Sara Grioni, Claudia Agnoli, Vittorio Krogh, Valeria Pala, Sabina Rinaldi, Marco Vinceti, Paolo Contiero, Luciano Vescovi, Marcella Malavolti, Sabina Sieri
Diet is the primary source of cadmium - a proven Group 1 human carcinogen - for non-smokers. Observational studies investigating the effect of cadmium from food sources on breast cancer risk have produced inconsistent results. We examined the association between dietary cadmium and risk of breast cancer defined by estrogen receptor (ER), progesterone receptor (PR) and HER2 status, in 8,924 women recruited to a prospective study between 1987 and 1992. Dietary cadmium intake was estimated using a semi-quantitative food frequency questionnaire at baseline...
December 4, 2018: International Journal of Cancer. Journal International du Cancer
Tanja Fehm, Volkmar Müller
Within the last years significant improvements have been achieved in early and metastatic breast cancer treatment by innovative targeted therapies and new drug combinations. GnRH-analogues have been confirmed as an important part of endocrine treatment in premenopausal patients. Endocrine based strategies including CDK-4/6-Inhibitors substantially improve progression-free survival in metastatic patients. For patients with HER2-positive disease the addition of Pertuzumab to Trastuzumab in combination with chemotherapy has achieved a significant improvement in anti-HER2 therapy in early as well as metastatic breast cancer...
December 2018: Deutsche Medizinische Wochenschrift
Mohammad Fararouei, Aqsa Iqbal, Shahab Rezaian, Zahra Gheibi, Aria Dianatinasab, Saba Shakarami, Mostafa Dianatinasab
BACKGROUND: Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or limited knowledge is available from the developing world. PATIENTS AND METHODS: This case-control study was performed from November 2014 to March 2016 on 1010 young women aged 20 to 50 years who were newly diagnosed with BC...
November 2, 2018: Clinical Breast Cancer
Minouk J Schoemaker, Michael E Jones, Craig D Higgins, Alan F Wright, Anthony J Swerdlow
The constitutional t(11;22)(q23;q11) translocation is the only recurrent non-Robertsonian translocation known in humans. Carriers are phenotypically normal and are usually referred for cytogenetic testing because of multiple miscarriages, infertility, or having aneuploidy in offspring. A breast cancer predisposition has been suggested, but previous studies have been small and had methodological shortcomings. We therefore conducted a long-term prospective study of cancer and mortality risk in carriers. We followed 65 male and 101 female carriers of t(11;22)(q23;q11) diagnosed in cytogenetic laboratories in Britain during 1976-2005 for cancer and deaths for an average of 21...
November 29, 2018: International Journal of Cancer. Journal International du Cancer
Sopit Tubtimhin, Supannee Promthet, Krittika Suwanrungruang, Pongsatorn Supaattagorn
Background and Purpose: This study focused on molecular subtypes and prognostic factors for survival of preand post-menopausal breast cancer patients. Methods: A retrospective cohort study was performed on 523 patients with invasive carcinoma of the breast treated at Ubon Ratchathani Cancer Hospital,Thailand from 2002 to 2016. Patient characteristics were collected based on a systematic chart audit from medical records. Prognostic factors were performed by observe survival analysis. A Cox regression model was used to calculate hazard ratios of death, taking into account the age and menopause status, molecular subtype, stage of disease, histological grade, lymphatic and vascular invasion, resection margin, hormone receptor expression, and treatment modality...
November 29, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
Macrene Alexiades
Genitourinary syndrome of menopause (GSM), encompassing the disorders of atrophic vaginitis, urinary incontinence, and pelvic prolapse, affects the majority of postmenopausal women, as well as patients who are undergoing breast cancer treatement, post-ovarectomy, post-radiation, and breast-feeding. There is a need for better treatment options for these common conditions that adversely affect physical function and quality of life and that are often underserved by existing options. Lasers have been used to treat genitourinary tissue for over 40 years, and over the past decade, several lasers and radiofrequency devices have been developed and clinically tested for the treatment of GSM, with an accumulating body of evidence demonstrating their safety and efficacy...
December 2018: Seminars in Cutaneous Medicine and Surgery
Yunan Han, Xiaoyu Zong, Yize Li, Graham A Colditz, Adetunji T Toriola
PURPOSE: Mammographic density is a strong risk factor for breast cancer. Although diet is associated with breast cancer risk, there are limited studies linking adult diet, including milk intake, with mammographic density. Here, we investigate the association of milk intake with mammographic density in premenopausal women. METHODS: We analyzed data from 375 cancer-free premenopausal women who had routine screening mammography at Washington University School of Medicine, St...
November 20, 2018: Breast Cancer Research and Treatment
Elina Holopainen, Svetlana Vakkilainen, Outi Mäkitie
BACKGROUND: Patients with cartilage-hair hypoplasia (CHH), a rare metaphyseal chondrodysplasia, manifest severe growth failure, variable immunodeficiency and increased risk of malignancies. The impact of CHH on gynecologic and reproductive health is unknown. Vulnerability to genital infections may predispose CHH patients to prolonged human papillomavirus (HPV) infections potentially leading to cervical, vaginal and vulvar cancer. METHODS: We carried out gynecologic evaluation, pelvic ultrasound and laboratory assessment in 19 women with genetically confirmed CHH...
November 16, 2018: Orphanet Journal of Rare Diseases
Mary Pegington, D Gareth Evans, Anthony Howell, Louise S Donnelly, Julia Wiseman, Jack M Cuzick, Michelle N Harvie
Women at increased breast cancer (BC) risk are eligible for chemoprevention. Healthy lifestyles are potentially important for these women to improve efficacy and minimise side effects of chemoprevention and reduce the risk of BC and other lifestyle-related conditions. We investigated whether women taking chemoprevention adhere to healthy lifestyle recommendations, how their lifestyle risk factors and health measures compare to women in the general population, and whether these change whilst taking chemoprevention...
November 15, 2018: European Journal of Cancer Prevention
Bielčiková Zuazana, Petruželka Luboš, Chloupková Renata
BACKGROUND: Trastuzumab (Herceptin® - H) has been the standard-of-care for patients with HER2+ breast cancer (BC) since 2009 in the Czech Republic. Neoadjuvant application of H increases the number of patients who achieve pathological complete remission (pCR) and improves patients' outcomes. AIM: This study aimed to assess the effect of neoadjuvant therapy (NAT) with H in patients with early HER2+ BC and to correlate the therapeutic outcome with overall survival (OS)...
2018: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
Yue-Lin Li, Ya-Chao Qin, Lu-Ying Tang, Yu-Huang Liao, Wei Zhang, Xiao-Ming Xie, Qiang Liu, Ying Lin, Ze-Fang Ren
Purpose: This study differentiates patient and care delays of breast cancer and explores the related factors as well as the associations with the prognosis in Guangzhou, a southern city of China. Methods: A cohort of female incident breast cancer patients (n=1,551) was recruited from October 2008 to March 2012 and followed up until January 1, 2016 (n=1,374) in the affiliated hospitals of Sun Yat-sen University. The factors associated with patient and care delays were analyzed with multivariable logistic models...
November 6, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
Yoshikazu Johmura, Ichiro Maeda, Narumi Suzuki, Wenwen Wu, Atsushi Goda, Mariko Morita, Kiyoshi Yamaguchi, Mizuki Yamamoto, Satoi Nagasawa, Yasuyuki Kojima, Koichiro Tsugawa, Natsuko Inoue, Yasuo Miyoshi, Tomo Osako, Futoshi Akiyama, Reo Maruyama, Jun-Ichiro Inoue, Yoichi Furukawa, Tomohiko Ohta, Makoto Nakanishi
The agonistic/antagonistic biocharacter of selective estrogen receptor modulators (SERMs) can have therapeutic advantages, particularly in the case of premenopausal breast cancers. Although the contradictory effects of these modulators have been studied in terms of crosstalk between the estrogen receptor α (ER) and coactivator dynamics and growth factor signaling, the molecular basis of these mechanisms is still obscure. We identify a series of regulatory mechanisms controlling cofactor dynamics on ER and SERM function, whose activities require F-box protein 22 (Fbxo22)...
November 12, 2018: Journal of Clinical Investigation
Jing-Min Dong, Hong-Xia Wang, Xiao-Fei Zhong, Kun Xu, Jia Bian, Yan Feng, Liang Chen, Lin Zhang, Xia Wang, De-Jing Ma, Bin Wang
This study aimed to analyze the relationship between pathologic complete response (pCR) and changes in background parenchymal enhancement (BPE) levels in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and who received neoadjuvant chemotherapy (NAC).The pre- and post-NAC magnetic resonance imaging results of 51 patients with confirmed unilateral HER2-positive breast cancer were retrospectively analyzed by 2 experienced radiologists. Pre- and post-NAC of contralateral BPE levels were classified into 4 categories (1 = minimal, 2 = mild, 3 = moderate, and 4 = marked)...
October 2018: Medicine (Baltimore)
Tanja Nadine Stueber, Claire Rachel Weiss, Achim Woeckel, Sebastian Haeusler
BACKGROUND: To examine influences on the receptor status of a local cohort of patients with recurrent breast cancer after primary diagnosis of hormone receptor positive breast cancer. METHODS: We retrospectively analyzed 2078 female patients with primary hormone receptor positive breast cancer treated at the university hospital of Wuerzburg between 2000 and 2013. Main focus was on discordance in receptor status in recurrent disease. RESULTS: 196 patients with the primary diagnosis of hormone receptor positive breast cancer developed recurrent disease...
November 8, 2018: Archives of Gynecology and Obstetrics
Cong Xue, Wenwen Wei, Peng Sun, Wei Zheng, Xiaoju Diao, Fei Xu, Jiajia Huang, Xin An, Wen Xia, Ruoxi Hong, Kuikui Jiang, Riqing Huang, Zhongyu Yuan, Shusen Wang, Anhua Li, Ruhai Zou, Yanxia Shi
PURPOSE: Ovarian function is important for optimizing endocrine treatment in patients with hormone receptor-positive (HR+) early breast cancer (eBC). The aim of the study was to determine whether patients' pretreatment levels of anti-Mullerian hormone (AMH) were associated with menses status after chemotherapy and to build a predictive nomogram model for amenorrhea in women with HR+ eBC. METHODS: Between August 2013 and December 2014, 120 premenopausal patients with HR+ eBC were included retrospectively...
November 3, 2018: Breast Cancer Research and Treatment
John L Hopper, Gillian S Dite, Robert J MacInnis, Yuyan Liao, Nur Zeinomar, Julia A Knight, Melissa C Southey, Roger L Milne, Wendy K Chung, Graham G Giles, Jeanine M Genkinger, Sue-Anne McLachlan, Michael L Friedlander, Antonis C Antoniou, Prue C Weideman, Gord Glendon, Stephanie Nesci, Irene L Andrulis, Saundra S Buys, Mary B Daly, Esther M John, Kelly Anne Phillips, Mary Beth Terry
BACKGROUND: The association between body mass index (BMI) and risk of breast cancer depends on time of life, but it is unknown whether this association depends on a woman's familial risk. METHODS: We conducted a prospective study of a cohort enriched for familial risk consisting of 16,035 women from 6701 families in the Breast Cancer Family Registry and the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer followed for up to 20 years (mean 10...
November 3, 2018: Breast Cancer Research: BCR
Taryn L Cranford, Kandy T Velázquez, Reilly T Enos, Alexander T Sougiannis, Jackie E Bader, Meredith S Carson, Rebecca R Bellone, Ioulia Chatzistamou, Mitzi Nagarkatti, E Angela Murphy
Clinical studies provide strong evidence that obesity and associated adipose tissue (AT) inflammation are risk factors for breast cancer (BrCA); however, mechanistic knowledge of the interaction of obesity, BrCA, and menopausal status has proven to be not only lacking, but contradictory. Obesity-induced inflammation and elevated biosynthesis of estrogens, through aromatase-mediated metabolism of precursors, have been linked with hormone receptor positive (HP) postmenopausal BrCA but not previously associated with premenopausal BrCA risk...
November 2, 2018: Cancer Biology & Therapy
Halle C F Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre, Anna Moseley, David J Porter, Prudence A Francis, Lori J Goldstein, Henry L Gomez, Carlos S Vallejos, Ann H Partridge, Shaker R Dakhil, Agustin A Garcia, Julie R Gralow, Janine M Lombard, John F Forbes, Silvana Martino, William E Barlow, Carol J Fabian, Lori M Minasian, Frank L Meyskens, Richard D Gelber, Gabriel N Hortobagyi, Kathy S Albain
Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen...
October 27, 2018: Journal of the National Cancer Institute
Shang Cao, Jinyi Zhou, Zheng Zhu, Feiran Wei, Wei Li, Shurong Lu, Jian Su, Hao Yu, Wencong Du, Lan Cui, Pingmin Wei, Ming Wu
PURPOSE: The accumulating evidence indicates that weight gain in adulthood is more predictive of breast cancer risk than absolute body weight. However, the relative impact of timing of weight gain in adulthood on breast cancer as well as other characteristics of the association between weight and breast cancer has not been well documented. METHODS: This population-based case-control study of breast cancer included 818 patients with newly diagnosed primary breast cancer and 935 residence and age-matched healthy controls...
October 27, 2018: Breast Cancer Research and Treatment
Kejia Hu, Ping He, Qian Peng, Xiaorong Zhong, Ling Deng, Yuxin Xie, Jiayuan Li, Hongping Xu, Donghao Lu, Hong Zheng
BACKGROUND: Ovarian function suppression (OFS) plus other endocrine treatment was recommended to hormone receptor (HR)-positive breast cancer by some guidelines recently. We performed this study to validate the survival benefits of OFS plus aromatase inhibitors (AI) or selective estrogen receptor modulators (SERM) in the real world. METHODS: All premenopausal, HR-positive breast cancer patients diagnosed between 1996 and 2017 were identified. Eligible patients were classified into three groups according to their adjuvant endocrine treatment, including OFS plus AI, OFS plus SERM and SERM alone...
October 26, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"